Empowered by high-end technologies and extensive experience in the field of antibody discovery and immunotherapy, Creative Biolabs now offers one-stop TCR-like antibody discovery service by versatile strategies to our worldwide clients for academic or clinical purposes.
1. Introduction of TCR-Like Antibody
Therapeutic antibodies have evolved into an effective treatment for cancer in the past decade. Many of these antibodies target tumor antigens expressed on the surfaces of tumor cells. However, the number of known antigens expressed exclusively on tumor cells is limited. Therefore, development of antibodies against disease-associated MHC–peptide complexes might lead to a new class of anticancer therapeutic antibodies. To achieve this goal, recombinant antibodies, termed TCR-like antibodies, are developed to bind specific MHC–peptide complexes in a peptide-specific, MHC-restricted, TCR-like manner. These antibodies mimic the fine specificity of tumor recognition by T cells. Meanwhile, they were demonstrated to be a unique research tool for studying specific antigen presentation on malignant and infected cells.
Fig 1 TCR-like monoclonal antibody binds to a peptide/MHC complex on a cancer cell. (Dao T, et.al. 2013)
2. Strategies to Generate TCR-Like Antibody
Antibodies with MHC-restricted specificity of T cells have been traditionally rare and difficult to generate. While, given to tireless efforts, skillful scientists from Creative Biolabs are proud to introduce versatile approaches to generate high affinity binders against certain targets using either conventional hybridoma or phage-display technology.
Hybridoma technology has long been the classic approach and milestone for the generation of monoclonal antibodies. As a well-established methodology, hybridoma technology has a tendency for isolating antibodies with high-affinity binding to the MHC–peptide complex (low nanomolar range). Although peptide-specific, MHC-restricted antibodies are quite rare even under optimal conditions, Creative Biolabs has high-throughput screening platforms to isolation desired antibodies out of a few thousands of clones.
Phage display emerged as a promising alternative for antibody generation. We are capable of selection binders from native libraries or libraries derived from immunized animal hosts. TCR-like antibodies isolated from phage display libraries are in a monovalent antibody form (Fab or scFv fragments) and can be produced in bacterial expression systems with relatively high yields of stable and purified antibody. Meanwhile, to increase the binding avidity and consequently the binding intensity of specific MHC–peptide complexes, Fab or scFv-tetramers can be generated on our platform.
Fig 2 Monoclonal antibody production by hybridoma and phage display technology.
3. Highlight Features of Our Service
➢ One-stop pipeline
Our all-round platform supports customized TCR-like antibody discovery from MHC/peptide complex preparation, animal immunization, high-affinity binders enrichment and selection, to scale-up monoclonal antibody production and characterization.
➢ Flexible options
We provide both hybridoma and phage display to generate TCR-like antibody with different affinity according to your specific requirement. Besides, our high-throughput selection approaches can be easily incorporated into these strategies. Moreover, several ready-to-use premade human scFv/Fab libraries are available to directly obtain human binders in a time-saving manner.
➢ Multiple immunization hosts
Creative Biolabs has developed various immunization methods for a dozen of hosts (rat, mouse, camel, monkey, rabbit, chicken, horse, etc). Of note, we also have several humanized transgenic mouse strains to produce fully human antibodies in mice. We are experts at raising strong immune responses against challenging immunogens.
➢ Ph.D. scientific team
Timely troubleshooting is promised to guarantee the highest success rate of each project.
With years of experience, Creative Biolabs has won good reputation in the field of antibody discovery. We keep close relationship with customers from either academic institution or pharmaceutical area. We are more than happy to share our technologies and experience to facilitate your projects and push the progress towards pre-clinical trials. Please feel free to contact us for more details.
Dao T, Liu C, Scheinberg DA. (2013). Approaching untargetable tumor-associated antigens with antibodies. Oncoimmunology. 2(7), e24678.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE